Anke H. Maitland‐van der Zee

17.3k total citations · 3 hit papers
295 papers, 6.6k citations indexed

About

Anke H. Maitland‐van der Zee is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pharmacology. According to data from OpenAlex, Anke H. Maitland‐van der Zee has authored 295 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Pulmonary and Respiratory Medicine, 95 papers in Physiology and 59 papers in Pharmacology. Recurrent topics in Anke H. Maitland‐van der Zee's work include Asthma and respiratory diseases (92 papers), Pharmacogenetics and Drug Metabolism (54 papers) and Respiratory and Cough-Related Research (51 papers). Anke H. Maitland‐van der Zee is often cited by papers focused on Asthma and respiratory diseases (92 papers), Pharmacogenetics and Drug Metabolism (54 papers) and Respiratory and Cough-Related Research (51 papers). Anke H. Maitland‐van der Zee collaborates with scholars based in Netherlands, United Kingdom and United States. Anke H. Maitland‐van der Zee's co-authors include Anthonius de Boer, Susanne J. H. Vijverberg, Mia Wadelius, Ann K. Daly, Tom Schalekamp, Talitha I. Verhoef, Munir Pirmohamed, Olaf H. Klungel, Jesse J. Swen and Paul Brinkman and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Blood.

In The Last Decade

Anke H. Maitland‐van der Zee

277 papers receiving 6.4k citations

Hit Papers

Pharmacogenetics: From Bench to Byte— An Update of Guidel... 2011 2026 2016 2021 2011 2013 2023 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pharmacogenetics: From Bench to Byte— An Update of Guidelines
    2011 747 citations Anthonius de Boer, Anke H. Maitland‐van der Zee et al. profile →
  2. A Randomized Trial of Genotype-Guided Dosing of Warfarin
    2013 590 citations Munir Pirmohamed, Anke H. Maitland‐van der Zee et al. profile →
  3. Identifying risk factors for COPD and adult-onset asthma: an umbrella review
    2023 68 citations Anke H. Maitland‐van der Zee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anke H. Maitland‐van der Zee Netherlands 39 1.9k 1.5k 1.2k 1.0k 936 295 6.6k
Michel Jadoul Belgium 55 1.1k 0.5× 620 0.4× 1.8k 1.5× 1.1k 1.1× 754 0.8× 270 11.5k
Håkan Melhus Sweden 48 796 0.4× 1.1k 0.7× 310 0.2× 2.2k 2.1× 1.0k 1.1× 172 9.1k
John F. Carlquist United States 47 829 0.4× 693 0.5× 533 0.4× 1.1k 1.1× 2.2k 2.3× 143 7.5k
Sudhir V. Shah United States 60 727 0.4× 809 0.5× 1.6k 1.3× 3.5k 3.3× 1.6k 1.7× 189 15.5k
E. Niclas Jonsson Sweden 37 762 0.4× 717 0.5× 728 0.6× 754 0.7× 386 0.4× 90 6.1k
E A Roberts Canada 19 723 0.4× 477 0.3× 952 0.8× 590 0.6× 738 0.8× 34 9.5k
Peter Höglund Sweden 51 384 0.2× 1.3k 0.8× 3.0k 2.4× 1.3k 1.3× 1.0k 1.1× 236 8.9k
Luis A. Garcı́a Rodrı́guez Spain 65 1.1k 0.5× 1.0k 0.7× 1.8k 1.4× 1.2k 1.2× 3.8k 4.1× 282 15.3k
Einar S. Björnsson Iceland 65 6.3k 3.2× 866 0.6× 1.3k 1.0× 1.2k 1.2× 564 0.6× 311 17.4k
Guruprasad P. Aithal United Kingdom 58 5.0k 2.6× 1.0k 0.7× 1.1k 0.9× 1.8k 1.8× 705 0.8× 304 16.5k

Countries citing papers authored by Anke H. Maitland‐van der Zee

Since Specialization
Citations

This map shows the geographic impact of Anke H. Maitland‐van der Zee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anke H. Maitland‐van der Zee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anke H. Maitland‐van der Zee more than expected).

Fields of papers citing papers by Anke H. Maitland‐van der Zee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anke H. Maitland‐van der Zee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anke H. Maitland‐van der Zee. The network helps show where Anke H. Maitland‐van der Zee may publish in the future.

Co-authorship network of co-authors of Anke H. Maitland‐van der Zee

This figure shows the co-authorship network connecting the top 25 collaborators of Anke H. Maitland‐van der Zee. A scholar is included among the top collaborators of Anke H. Maitland‐van der Zee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anke H. Maitland‐van der Zee. Anke H. Maitland‐van der Zee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Terheggen‐Lagro, Suzanne W. J., Eric G. Haarman, Simone Hashimoto, et al.. (2025). Real-world pharmacokinetics of elexacaftor-tezacaftor-ivacaftor in children with cystic fibrosis: a prospective observational study. Journal of Cystic Fibrosis. 24(3). 526–533. 1 indexed citations
2.
Hashimoto, Simone, Niels W. Rutjes, Korneliusz Golebski, et al.. (2024). Factors influencing the initiation of biologic therapy in children with severe asthma: Results of the pediatric asthma noninvasive diagnostic approaches (PANDA) study. Pediatric Pulmonology. 59(11). 2875–2884. 1 indexed citations
3.
Schee, Marc P. van der, et al.. (2024). Influence of the gut and airway microbiome on asthma development and disease. Pediatric Allergy and Immunology. 35(3). e14095–e14095. 4 indexed citations
4.
Brinkman, Paul, Michael Wilde, Waqar Ahmed, et al.. (2024). Fulfilling the Promise of Breathomics: Considerations for the Discovery and Validation of Exhaled Volatile Biomarkers. American Journal of Respiratory and Critical Care Medicine. 210(9). 1079–1090. 6 indexed citations
5.
Finnicum, Casey T., Lannie Ligthart, Jouke‐Jan Hottenga, et al.. (2024). Epigenetic signatures of asthma: a comprehensive study of DNA methylation and clinical markers. Clinical Epigenetics. 16(1). 151–151. 4 indexed citations
6.
Hayfron‐Benjamin, Charles, Charles Agyemang, Bert‐Jan H. van den Born, et al.. (2023). Associations between spirometric impairments and microvascular complications in type 2 diabetes: a cross-sectional study. BMJ Open. 13(10). e075209–e075209. 1 indexed citations
7.
Neumann, Eva, Jethro Herberg, Évelyne Jacqz-Aigrain, et al.. (2022). How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper. British Journal of Clinical Pharmacology. 88(12). 5017–5033. 3 indexed citations
8.
Hagens, Laura A., Marry R. Smit, Nanon F. L. Heijnen, et al.. (2022). Validation of volatile metabolites of pulmonary oxidative injury: a bench to bedside study. ERJ Open Research. 9(2). 427–2022. 8 indexed citations
9.
Slob, Elise M. A., Cristina Longo, Susanne J. H. Vijverberg, et al.. (2022). Persistence of parental‐reported asthma at early ages: A longitudinal twin study. Pediatric Allergy and Immunology. 33(3). e13762–e13762. 7 indexed citations
10.
Porsbjerg, Celeste, Sisse B. Ditlev, Ditte Kjærsgaard Klein, et al.. (2021). Treating severe asthma: Targeting the IL‐5 pathway. Clinical & Experimental Allergy. 51(8). 992–1005. 47 indexed citations
11.
Neerincx, Anne H., Katrine Whiteson, Paul Brinkman, et al.. (2021). Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients. ERJ Open Research. 7(2). 731–2020. 24 indexed citations
12.
Bragt, Job J.M.H. van, Simone Hashimoto, Paul Brinkman, et al.. (2021). Exhaled Metabolite Patterns to Identify Recent Asthma Exacerbations. Metabolites. 11(12). 872–872. 4 indexed citations
13.
Bragt, Job J.M.H. van, Susanne Hansen, Ratko Djukanović, et al.. (2021). SHARP: enabling generation of real-world evidence on a pan-European scale to improve the lives of individuals with severe asthma. ERJ Open Research. 7(2). 64–2021. 9 indexed citations
14.
Brinkman, Paul, Rianne de Vries, Pieter-Jan Am van Ooij, et al.. (2019). Detecting Pulmonary Oxygen Toxicity Using eNose Technology and Associations between Electronic Nose and Gas Chromatography–Mass Spectrometry Data. Metabolites. 9(12). 286–286. 4 indexed citations
15.
Siddiqui, Moneeza K., Abirami Veluchamy, Cyrielle Maroteau, et al.. (2017). CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. Circulation Cardiovascular Genetics. 10(4). 3 indexed citations
16.
Veldhuis‐Vlug, Annegreet G., Ling Oei, Patrick C. Souverein, et al.. (2015). Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density. Osteoporosis International. 26(7). 2019–2027. 12 indexed citations
17.
Eng, Lawson, Abul Kalam Azad, Steven Habbous, et al.. (2012). Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis. Clinical Cancer Research. 18(17). 4526–4537. 45 indexed citations
18.
Zee, Anke H. Maitland‐van der & Ann K. Daly. (2012). Pharmacogenetics and individualized therapy. John Wiley & Sons eBooks. 2 indexed citations
19.
Schie, Rianne MF van, Talitha I. Verhoef, Tom Schalekamp, et al.. (2012). Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose. Drug metabolism and drug interactions. 27(4). 229–234. 5 indexed citations
20.
Koster, Ellen S., Jan A. M. Raaijmakers, Susanne J. H. Vijverberg, & Anke H. Maitland‐van der Zee. (2011). Inhaled corticosteroid adherence in paediatric patients: the PACMAN cohort study. Pharmacoepidemiology and Drug Safety. 20(10). 1064–1072. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michel Jadoul Breakdown of academic impact, for papers by Håkan Melhus Breakdown of academic impact, for papers by John F. Carlquist Breakdown of academic impact, for papers by Sudhir V. Shah Breakdown of academic impact, for papers by E. Niclas Jonsson Breakdown of academic impact, for papers by E A Roberts Breakdown of academic impact, for papers by Peter Höglund Breakdown of academic impact, for papers by Luis A. Garcı́a Rodrı́guez Breakdown of academic impact, for papers by Einar S. Björnsson Breakdown of academic impact, for papers by Guruprasad P. Aithal
Rankless by CCL
2026